The Cataltheia Group and Bruno Vision Care Announce Publication of Landmark Clinical Study Validating Deseyne® Extended Depth of Focus Technology for Presbyopia
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, today announced the publication of landmark clinical data in Optometry and Vision Science (OVS), the official journal of the American Academy of Optometry, validating the performance of the Deseyne® contact lens — the first and only FDA-cleared daily disposable soft contact lens for presbyopia featuring Extended Depth of Focus (EDOF) technology.
Bruno Vision Care Wins 2026 MedTech Breakthrough Award
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that its Deseyne® daily disposable contact lens technology for presbyopia with Extended Depth of Focus (EDOF) is this year’s recipient of the “Best New Technology Solution - Ophthalmology” in the 2026 MedTech Breakthrough Awards. The MedTech Breakthrough Awards program recognizes the most innovative companies, technologies, and products in the global digital health and medical technology market.
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States.
Bruno Vision Care Receives FDA Approval for Deseyne® Contact Lens with FusionTechnology™
Bruno Vision Care LLC, a leader in eye care innovation, has received approval from the U.S. Food and Drug Administration (FDA) to sell its Deseyne® (vifilcon C) daily disposable contact lens with FusionTechnology™ in the United States.
